BioTime, Inc. and Abcodia Ltd. Company Profile

14:57 EST 18th December 2018 | BioPortfolio

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTime’s focus is on pluripotent stem cell technology based on human embryonic stem (“hES”) cells and induced pluripotent stem (“iPS”) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime’s therapeutic and research products include a wide array of proprietary PureStem® progenitors, HyStem® hydrogels, culture media, and differentiation kits. BioTime is developing Renevia™ (a HyStem® product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications, and is planning to initiate a pivotal clinical trial around Renevia™, in 2014. In addition, BioTime has developed Hextend®, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend® is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ HealthCare Corporation, under exclusive licensing agreements.

News Articles [52 Associated News Articles listed on BioPortfolio]

BioTime Acquires Two Clinical─Stage Cell Therapy Product Candidates Addressing Significant Unmet Needs in Spinal Cord Injury and Immuno─Oncology

BioTime, Inc, and Asterias Biotherapeutics, Inc, announced that they have entered into a definitive merger agreement whereby BioTime will acquire all of the remaining outstanding common stock of Aster...

Asterias Biotherapeutics to merge with BioTime

US-based biotechnology firms BioTime and Asterias Biotherapeutics have entered into a definitive merger agreement to form an integrated company focussed...Read More... The post Asterias Biotherapeutic...

BioTime spins out its early-stage technology into new company

BioTime Inc (NYSEAMERICAN:BTX) CEO Brian Culley sat down with Proactive Investors at the 11th Annual LD Micro Main Event in Los Angeles.  BioTime specializes in regenerative medicine and util...

Biotechnology firm BioTime to secure $43m from Juvenescence

Under the terms of the agreement, Juvenescence will purchase, in a single transaction, 14.4 million shares of AgeX Therapeutics from BioTime for $43.2 million. 50% of the purchase The post Biotechnol...

BioTime signs merger deal with Asterias Biotherapeutics

The merger of BioTime and Asterias Biotherapeutics will enable to create a major cell therapy company. As per terms of the deal, Asterias stockholders will secure 0.71 common The post BioTime signs m...

BioTime schließt Verkauf von AgeX-Anteilen an Juvenescence in Höhe von 43,2 Millionen USD ab

Erlös stellt BioTime ausreichend Kapital für die Finanzierung wichtiger Meilensteine aktueller Programme zur Verfügung, einschließlich Schlüsseldaten und Entscheidungen zu Renevia und OpRegen Bio...

Asterias and BioTime reverse merge to focus on cancer, neuro cell therapies

BioTime Inc. is re-acquiring an ownership stake in former subsidiary Asterias Biotherapeutics Inc., resulting in a merged cell therapy company in which Asterias will be the surviving entity and hold 1...

BioTime to Present at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer o...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [9 Associated Companies listed on BioPortfolio]

BioTime, Inc. and Abcodia Ltd.

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell ...

BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell techn...

BioTime Inc.

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime’s p...

BioTime, Inc. 

BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical ...

BioTime Incorporated

BioTime, Inc. (OTCBB: BTIM), based in Emeryville, California, is engaged in the research and development of aqueous-based synthetic solutions that may be used as plasma expanders, organ preservation s...

More Information about "BioTime, Inc. and Abcodia Ltd." on BioPortfolio

We have published hundreds of BioTime, Inc. and Abcodia Ltd. news stories on BioPortfolio along with dozens of BioTime, Inc. and Abcodia Ltd. Clinical Trials and PubMed Articles about BioTime, Inc. and Abcodia Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioTime, Inc. and Abcodia Ltd. Companies in our database. You can also find out about relevant BioTime, Inc. and Abcodia Ltd. Drugs and Medications on this site too.

Quick Search


Relevant Topic

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Corporate Database Quicklinks

Searches Linking to this Company Record